Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590525 · ClinicalTrials.gov registry record
Inflammation as a Predictor in Cardioversion of Atrial Fibrillation
A clinical trial, sponsored by Creighton University.
- Completed
- Registry status
- 45
- Enrollment target
NCT00590525 is a clinical trial that has completed, run by Creighton University. The registered enrollment target is 45 participants.
The verdict
NCT00590525 has completed, sponsored by Creighton University.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
The laboratory test, C-Reactive Protein (CRP), has become well established as a marker of inflammation. Recently a high CRP level (indicating an increase in inflammation) was identified as a risk factor for atrial fibrillation. We are conducting this study with patients such as yourself with atrial fibrillation who are planning to undergo cardioversion to determine what sort of relationship exists between CRP levels and atrial fibrillation. We will then look at success rates of converting atrial fibrillation to normal sinus rhythm, compared to patients' CRP levels.
Interventions
- PROCEDURE Cardioversion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2004-10 |
| Est. Completion | 2009-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00590525
The ClinicalTrials.gov registry entry for NCT00590525 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Creighton University, which has 98 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cardioversion is the first listed.
NCT00590525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00590525 about?
NCT00590525 is a clinical study titled "Inflammation as a Predictor in Cardioversion of Atrial Fibrillation". The laboratory test, C-Reactive Protein (CRP), has become well established as a marker of inflammation. Recently a high CRP level (indicating an increase in inflammation) was identified as a risk factor for atrial fibrillation. We are conducting this study with patients such as yourself with atrial ...
What is the current status of trial NCT00590525?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2004-10. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00590525?
The interventions under investigation include: Cardioversion (PROCEDURE).
Who is sponsoring clinical trial NCT00590525?
This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.